A Phase 3 interventional study of Viaskin Peanut 250mcg and Placebo in Peanut Allergy, sponsored by DBV Technologies. Completed at 31 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 4 in phase 3, and was the 4th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →
Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2015.
This study's enrollment of 500 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 105 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
13 studies in Peanut Hypersensitivity by DBV Technologies: none open now, 2 under way, 2 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 13 studies in Peanut Hypersensitivity by DBV Technologies, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 7 in phase 3, and was the 4th registered.
DBV Technologies’s Peanut Hypersensitivity studies by the year they started, since 2010.
1 of the studies testing palforzia in Peanut Hypersensitivity that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, from their registry updates:
Among DBV Technologies’s 13 in Peanut Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).
This is a 12-month, Phase III, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of Viaskin Peanut, dosed at 250µg peanut protein (per patch) in peanut-allergic children from 4 through 11 years of age.
The overall maximum study duration for each subject is approximately 61 weeks (6-week screening period, 12-month treatment period and 2-week follow-up period).
During the screening period, subjects will undergo a first screening visit and an entry double-blind, placebo-controlled food challenge (DBPCFC) to peanut to confirm their allergy and their entry peanut eliciting dose (ED). The starting dose of the challenge will be 1 mg peanut protein and will escalate up to a highest dose of 300mg peanut protein. Subjects who react at or below the dose of 300mg peanut protein are considered eligible.
Randomization of eligible subjects will occur in a 2:1 ratio to Viaskin Peanut dosed at 250µg peanut protein (active treatment) or placebo. Subjects will be stratified at randomization by their entry/screening DBPCFC ED in 1 of the following 2 strata and by study center:
Subjects will apply a Viaskin patch containing either peanut protein or placebo daily for a period of 12 months. At Month 12, a post-treatment DBPCFC to peanut will be performed, with a starting dose of 1 mg peanut protein with escalation up to a highest dose of 2,000 mg peanut protein. This evaluation will help determine the primary efficacy endpoint of this pivotal study.
Main Inclusion Criteria:
Positive peanut skin prick test (SPT) with a largest wheal diameter:
Main Exclusion Criteria:
Diagnosis of asthma that fulfills any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One Viaskin epicutaneous delivery system (patch) containing 250 µg of peanut protein applied on the skin for 24 hours (±4 hours of allowance) daily for a period of 12 months.
Biological: Viaskin Peanut 250mcg
One Viaskin epicutaneous delivery system (patch) containing placebo applied on the skin for 24 hours (±4 hours of allowance) daily for a period of 12 months.
Biological: Placebo
Peanut extract cutaneous patch
Also known as: DBV712
Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population
The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.
Time frame: At Month 12
Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening Eliciting Dose (ED) Subgroup
The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.
Time frame: At Month 12
Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12
The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.
Time frame: Baseline and Month 12
Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time
Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.
Time frame: Baseline and Months 3, 6 and 12
Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time
Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.
Time frame: Baseline and Months 3, 6 and 12
This Phase III study was conducted in participants aged 4 to 11 years old with peanut allergy at 31 active centers in Australia, Canada, Germany, Ireland and USA. Participants were randomized in a 2:1 ratio to receive DBV712 250 micrograms (μg) (Viaskin® Peanut 250 μg) or placebo.
| Milestone | DBV712 250 μg | Placebo | Screened |
|---|---|---|---|
| Started | 0 | 0 | 500 |
| Completed | 0 | 0 | 356 |
| Not completed | 0 | 0 | 144 |
| Withdrew: Inclusion/exclusion failure | 0 | 0 | 117 |
| Withdrew: Withdrawal by subject | 0 | 0 | 23 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Other not specified | 0 | 0 | 3 |
| Milestone | DBV712 250 μg | Placebo | Screened |
|---|---|---|---|
| Started | 238 | 118 | 0 |
| Completed | 213 | 107 | 0 |
| Not completed | 25 | 11 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 |
| Withdrew: Non-compliance with the investigational product (ip) | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 6 | 0 |
| Withdrew: Other | 3 | 1 | 0 |
The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.
| percentage of participants | DBV712 250 μg | Placebo |
|---|---|---|
| Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population | 35.3 (29.5 to 41.6) | 13.6 (8.5 to 20.9) |
The Double-Blind Placebo-Controlled Food Challenges (DBPCFCs) to determine Eliciting Dose (ED) were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if: * ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or * ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2). Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.
| percentage of participants | DBV712 250 μg | Placebo |
|---|---|---|
| Screening ED subgroup 1 | 39.0 (25.7 to 54.3) | 20.0 (8.1 to 41.6) |
| Screening ED subgroup 2 | 34.5 (28.2 to 41.4) | 12.2 (7.1 to 20.2) |
The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.
| mg | DBV712 250 μg | Placebo |
|---|---|---|
| Baseline | 144.0 (44.0 to 444.0) | 144.0 (44.0 to 444.0) |
| Month 12 | 444.0 (144.0 to 1444.0) | 144.0 (44.0 to 444.0) |
Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.
| Percent of change | DBV712 250 μg | Placebo |
|---|---|---|
| Month 3 | 78.716 (26.557 to 174.588) | 16.964 (-12.591 to 48.802) |
| Month 6 | 39.716 (-3.676 to 109.690) | 4.605 (-26.380 to 30.352) |
| Month 12 | 2.858 (-24.739 to 61.058) | -6.919 (-31.468 to 25.291) |
Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.
| Percent of change | DBV712 250 μg | Placebo |
|---|---|---|
| Month 3 | 127.778 (55.660 to 259.615) | 14.286 (0.000 to 45.833) |
| Month 6 | 258.491 (107.843 to 549.351) | 11.492 (-9.677 to 42.105) |
| Month 12 | 513.487 (196.458 to 1105.235) | 10.496 (-10.108 to 33.333) |
Collected over Screened arm: Adverse Events (AEs) collected from signing the informed consent up to the end of the screening period. DBV712 250µg and placebo arms: Treatment-Emergent Adverse Events (TEAEs) collected from Day 1, throughout the 53-week treatment period and additional 2-week follow-up period. Overall time frame of up to 55 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBV712 250 μg | 0/238 (0%) | 10/238 (4.2%) | 222/238 (93.3%) |
| Placebo | 0/118 (0%) | 6/118 (5.1%) | 96/118 (81.4%) |
| Screened | 0/500 (0%) | 9/500 (1.8%) | 83/500 (16.6%) |
| Event | DBV712 250 μg | Placebo | Screened |
|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 6/238 | 3/118 | 8/500 |
| AppendicitisInfections and infestations | 1/238 | 1/118 | 0/500 |
| Visual impairmentEye disorders | 0/238 | 1/118 | 0/500 |
| Coeliac diseaseGastrointestinal disorders | 0/238 | 1/118 | 0/500 |
| Food allergyImmune system disorders | 1/238 | 0/118 | 0/500 |
| TonsillitisInfections and infestations | 1/238 | 0/118 | 0/500 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/238 | 0/118 | 0/500 |
| WheezingRespiratory, thoracic and mediastinal disorders | 1/238 | 0/118 | 0/500 |
| Encephalitis influenzalInfections and infestations | 0/238 | 0/118 | 1/500 |
| Event | DBV712 250 μg | Placebo | Screened |
|---|---|---|---|
| Application site pruritusGeneral disorders | 83/238 | 14/118 | 0/500 |
| Upper respiratory tract infectionInfections and infestations | 73/238 | 30/118 | 16/500 |
| Application site erythemaGeneral disorders | 67/238 | 20/118 | 0/500 |
| CoughRespiratory, thoracic and mediastinal disorders | 52/238 | 15/118 | 3/500 |
| PyrexiaGeneral disorders | 48/238 | 22/118 | 5/500 |
| Viral upper respiratory tract infectionInfections and infestations | 42/238 | 20/118 | 8/500 |
| HeadacheNervous system disorders | 39/238 | 18/118 | 5/500 |
| Application site swellingGeneral disorders | 38/238 | 2/118 | 0/500 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 30/238 | 16/118 | 2/500 |
| VomitingGastrointestinal disorders | 31/238 | 10/118 | 6/500 |
The intent-to-treat (ITT) population was comprised of all participants who were randomized.
| Age, Continuous(years) | DBV712 250 μg | Placebo | Total |
|---|---|---|---|
| Mean | 7.4 ± 2.11 | 7.3 ± 2.30 | 7.3 ± 2.17 |
| Age, Customized(Participants) | DBV712 250 μg | Placebo | Total |
|---|---|---|---|
| 4 to 5 years | 55 | 32 | 87 |
| 6 to 11 years | 183 | 86 | 269 |
| Sex: Female, Male(Participants) | DBV712 250 μg | Placebo | Total |
|---|---|---|---|
| Female | 89 | 49 | 138 |
| Male | 149 | 69 | 218 |
| Race/Ethnicity, Customized(Participants) | DBV712 250 μg | Placebo | Total |
|---|---|---|---|
| White | 194 | 96 | 290 |
| Black or African American | 1 | 2 | 3 |
| Asian | 19 | 8 | 27 |
| Other | 24 | 12 | 36 |
| Screening Eliciting Dose (ED) Subgroup(Participants) | DBV712 250 μg | Placebo | Total |
|---|---|---|---|
| Screening ED Subgroup 1 | 41 | 20 | 61 |
| Screening ED Subgroup 2 | 197 | 98 | 295 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2015, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2021, 4 years 1 month after primary completion. A results delay was requested in Feb 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palforzia
DBV Technologies